8-K: Leap Therapeutics Secures $40 Million in Private Placement to Advance Cancer Drug Development

Leap Therapeutics has announced a $40 million private placement to fund the expansion of its DKN-01 clinical trials and extend its cash runway into Q2 2026.

Summary

• Leap Therapeutics has entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds.
• The company will issue 12,660,993 shares of common stock at $2.82 per share and pre-funded warrants for 1,523,404 shares at $2.819 per share.
• The transaction is anticipated to close on April 15, 2024, pending customary closing conditions.
• The funds will be used to expand the DeFianCe study for DKN-01 in colorectal cancer from 130 to 180 patients, mature data in the DisTinGuish study for gastric cancer, and manufacture clinical trial material for Phase 3 readiness.
• The net proceeds, combined with existing cash, are expected to fund operations into the second quarter of 2026.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise and plans for clinical development. However, it also includes standard risk disclosures, which temper the overall sentiment.

Positives

• The $40 million private placement provides significant capital to advance the DKN-01 program.
• The expansion of the DeFianCe study will provide more data on DKN-01's efficacy in colorectal cancer.
• The funding will allow for the maturation of data from the DisTinGuish study in gastric cancer.
• Manufacturing clinical trial material for Phase 3 readiness positions the company for future development.
• The extended cash runway into Q2 2026 provides financial stability for ongoing operations.

Risks

• The closing of the private placement is subject to customary closing conditions, which may not be met.
• The company's ability to successfully execute clinical trials and the timing of enrollment may be subject to delays.
• Clinical trial results may not be favorable, impacting the future of the DKN-01 program.
• The company's ability to enter into new strategic partnerships and maintain existing collaborations is not guaranteed.
• Regulatory approvals for clinical trials and products are not assured.
• The company is exposed to risks from inflation, currency rate and interest rate fluctuations, and market price volatility.
• Global conflicts and supply chain issues may delay or adversely affect clinical trials and manufacturing.

Future Outlook

The company expects to use the net proceeds to advance its DKN-01 program, including expanding clinical trials, maturing data, and preparing for Phase 3, with the goal of extending the cash runway into Q2 2026.

Management Comments

• The company intends to use the net proceeds from the financing to fund the continued development of its lead monoclonal antibody program, DKN-01.
• The net proceeds from this financing, combined with existing cash, cash equivalents and marketable securities, are expected to fund Leaps operating and capital expenditures into the second quarter of 2026.

Industry Context

This private placement reflects the ongoing need for capital in the biotechnology sector to fund drug development. The focus on DKN-01, a monoclonal antibody, aligns with the industry's interest in targeted and immuno-oncology therapies. The involvement of Gilead Sciences, Inc. as an investor highlights the potential of Leap's programs.

Comparison to Industry Standards

• The use of private placements to raise capital is a common practice in the biotech industry, especially for companies in the clinical stage.
• The expansion of the DeFianCe study from 130 to 180 patients is a significant increase, indicating a strong commitment to the DKN-01 program.
• The focus on DKK1 as a target is notable, as it is a relatively novel target in cancer therapy.
• The company's stated goal of achieving Phase 3 readiness is a standard milestone for clinical-stage biotech companies.
• The cash runway extension to Q2 2026 is a positive sign for investors, providing a longer period of operational stability.

Stakeholder Impact

• Shareholders will see dilution from the issuance of new shares.
• Employees will benefit from the company's increased financial stability and continued operations.
• Patients may benefit from the advancement of DKN-01 and other programs.
• Creditors will have increased confidence in the company's ability to meet its obligations.
• Suppliers will have continued business with the company.

Next Steps

• The company will close the private placement on April 15, 2024.
• Leap will file a registration statement with the SEC to register the resale of the shares and warrants.
• The company will expand the DeFianCe study in colorectal cancer.
• Leap will continue to mature data in the DisTinGuish study for gastric cancer.
• The company will manufacture clinical trial material to permit Phase 3 readiness.

Key Dates

Keywords

private placement, DKN-01, colorectal cancer, gastric cancer, clinical trials, monoclonal antibody, oncology, biotechnology, securities, funding